Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs has developed various anti-FLT3-related products to support the development of CAR-T therapy.
FLT3 gene encodes a class III receptor tyrosine kinase. It plays a significant role in the development and regulation of hematopoiesis. FLT3 is associated with the progression of various cancers. FLT3 mutation occurs frequently in acute myeloid leukemia (AML), leading to abnormal constitutive activation of the receptor and uncontrolled cell growth. FLT3 inhibitors are being developed as targeted therapies for leukemia treatment. Anti-FLT3 antibodies have been developed to block its activation, thus inhibiting cell growth and promoting apoptosis. In addition, CAR-T cells expressing anti-FLT3 CARs are a promising therapy for the treatment of AML and other cancers that express FLT3.
Acute myeloid leukemia
Acute lymphoblastic leukemia
Chronic lymphocytic leukemia (CLL)
Multiple myeloma
Anti-FLT3 CAR-T Expression Test
At Creative Biolabs, we provide various methods (flow cytometry, qPCR, WB) and reagents (such as protein L and anti-Fab antibodies) to evaluate anti-FLT3 CAR expression.
Fig.1 Flow cytometry analysis of GFP and FLT3L expression on FLT3L CAR-T cells. The figure shows that FLT3L-specific CAR-T cells effectively express the FLT-3 ligand.1
Anti-FLT3 CAR-T Cytokine Release Test
We provide comprehensive cytokine release test services using ELISA, ELISPOT, and multiplex bead array. By detecting a wide range of cytokines, including IL-2, TNF-α, and IFN-γ, the test can help researchers identify efficiency and the potential side effects associated with the CAR-T treatment.
Fig.2 The expression of cytokines in CD19 CAR-T cells co-cultured with leukemia cells. The cytokines IFN-γ, TNF-α, and IL-2 in the supernatants are significantly increased and show high-level IFN-γ release.1
Anti-FLT3 CAR-T In Vitro Cytotoxicity Assay
Our CAR-T cell cytotoxicity assay services are highly sensitive methods that measure the ability of CAR-T cells to recognize and kill tumor cells in vitro.
Fig.3 Cytotoxicity of FLT3L CAR-T against FLT3+ or FLT3- AML cell lines. FLT3L CAR-T cells exhibited antigen-specific cytotoxicity against FLT3+ leukemia cells.1
Efficacy Test of Anti-FLT3 CAR-T
At our lab, we are dedicated to offering comprehensive in vivo CAR-T cell therapy testing services. We evaluate the antitumor activity of CAR-T cells in vivo by detecting tumor growth and mouse survival.
Fig.4 In vivo evaluation of FLT3 CAR-T efficacy in a xenograft model of AML in immunodeficient mice. A) BLI showed leukemia progression. B) Flow cytometric analysis of peripheral blood after leukemia inoculation.2
Toxicity Evaluation Anti-FLT3 CAR-T
Our comprehensive services for in vivo CAR-T cell therapy testing include toxicity evaluation and therapeutic efficacy assessment. For toxicity evaluation, we use appropriate models to evaluate the toxicity of CAR-T cells, including tumorigenicity study, on-target toxicity, and off-target toxicity.
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-0722-LX39 | Anti-FLT3 (X7X39) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X39 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX40 | Anti-FLT3 (X7X40) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X40 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX42 | Anti-FLT3 (X7X42) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X42 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX43 | Anti-FLT3 (X7X43) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X43 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX44 | Anti-FLT3 (X7X44) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X44 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX45 | Anti-FLT3 (X7X45) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X45 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX46 | Anti-FLT3 (X7X46) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X46 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX47 | Anti-FLT3 (X7X47) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X47 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX48 | Anti-FLT3 (X7X48) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X48 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX49 | Anti-FLT3 (X7X49) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | human | X7X49 | humanized | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX187 | Anti-FLT3 (X7X187) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | Human | X7X187 | Human | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX188 | Anti-FLT3 (X7X188) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | Human | X7X188 | Human | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX189 | Anti-FLT3 (X7X189) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | Human | X7X189 | Human | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX190 | Anti-FLT3 (X7X190) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | Human | X7X190 | Human | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0722-LX605 | Anti-FLT3 (X7X189) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X7X189 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-LX606 | Anti-FLT3 (X7X190) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X7X190 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-LX607 | Anti-FLT3 (X7X191) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X7X191 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-LX608 | Anti-FLT3 (X7X192) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X7X192 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-LX609 | Anti-FLT3 (X7X193) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X7X193 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-LX610 | Anti-FLT3 (X7X194) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X7X194 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0823-LX47 | Anti-hFLT3 (AB) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | AB | Adenoviral vectors |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
